Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 24 of 24 publications.
Skip to main content
Eiden AL, Hartley L, Garbinsky D, Saande C, Russo J, Gabriel MH, Price M, Bhatti A. Adult vaccination coverage in the United States: a database analysis and literature review of improvement strategies. Hum Vaccin Immunother. 2024 Dec 31;20(1):2381283. doi: 10.1080/21645515.2024.2381283
Chapman KR, Guyot P, Ledanois O, Soliman M, Wang Z, Xu Y, Nangia A, Cheng W-H. Efficacy of dupilumab versus tezepelumab in asthma patients: matching-adjusted indirect comparison of long-term extension trials. Poster presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting; October 25, 2024. Boston, MA.
Gildea L, Copley-Merriman C, Arvin-Berod C, Vande Walle K, Verheesen P, Stoykov I. Evidence gap analysis of the burden of illness and treatment of bullous pemphigoid. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S27. doi: 10.1016/j.jval.2023.09.141
Whalley D, Belongie K, Frangiosa T, Krasa H, Mladsi DM, Twiss J, Wolowacz S. Understanding the patient experience of erythropoietic protoporphyria and x-linked protoporphyria: a qualitative study. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, Danysh HE, Ritchey ME, Demos G. Falls and fractures in patients with Parkinson's Disease–related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022 Mar;9(1):9-22. doi: 10.1007/s40801-021-00284-1
Lunan M, Hartley L, Pearson I, Doyle S. Targeted literature review of the burden of illness in late-stage Duchenne Muscular Dystrophy (DMD). Poster presented at the Virtual ISPOR Europe 2021; November 3, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021 Jan 27. doi: 10.1371/journal.pone.0246121
Garcia de Albeniz X, Riera Guardia N, Gutierrez L, Bahmanyar S, Blin P, Droz C, Heinig M, Linder M, Moore N, Schulze-Rath R, Sultana J, Trifiro G, Zhang WW, Zong J. Feasibility of studying the use of tissue-agnostic cancer drugs in population-based European health databases. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Cawson M, Wolowacz S, Doward L, Sinha A. Health utility estimates for congenital cytomegalovirus disease: conceptual design considerations. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Nance R, Vannappagari V, Johannes C, Calingaert B, Saltus C, Boswell S, Rodriguez B, Moore R, Eron J, Geng E, Mathews WC, Saag MS, Kitahata M, Delaney JAC, Crane HM, Centers For AIDS Research Network of Integrated Clinical Systems (CNICS). Viral failure among persons living with HIV initiating dolutegravir-based vs. other recommended regimens in real-world clinical care settings. Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct 4; 4((Suppl 1)):S39. doi: 10.1093/ofid/ofx162.095
Graham CN, McBride D, Miles L, Kneidl J, Mollon P. Estimation of indirect (work-related productivity) costs associated with moderate-to-severe plaque psoriasis in Germany. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J. Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
D'Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Graham CN, Mollon P, Miles L, McBride D. A new cost-effectiveness framework for modeling psoriasis treatment. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring utility for economic models within clinical trials: can we do better? Presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Roskell N, Mendelson E, Whalley D, Knight CJ. Using a condition-specific measure of patient-reported outcomes to derive utilities in myelofibrosis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A224-5.
Wolowacz S, Jhaveri M, Tangirala K. Cost-utility model to evaluate adjuvant chemotherapy for early breast cancer in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009.
Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.
Pattanayak SK, Poulos C, Yang JC, Patil SR, Wendland KJ. Of taps and toilets: quasi-experimental protocol for evaluating community-demand-driven projects. J Water Health. 2009 Sep 1;7(3):434-51.
Wolowacz SE, Roskell NS, Maciver F, Kelly S. Cost-utility analysis for pegaptanib in age-related macular degeneration in the UK: the impact of demographic and disease characteristics. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Lewis SA. A practical walkthrough of an epro design kickoff. Benefits and challenges with epro: outcomes and endpoints as we emerge from the long age of paper methods. Presented at the Drug Information Association conference workshop; 2005.
Doward LC, McKenna SP, Meads DM, Ratcliffe J, Whalley D, Langley PC. Investigation into the feasibility of deriving relative and absolute utility from the recurrent genital herpes quality of life questionnaire (RGHQOL). Poster presented at the 2002 ISPOR 5th Annual European Congress; November 2002. Rotterdam, The Netherlands. [abstract] Value Health. 2002 Nov; 5(6):573-4.
Funch DP, Rothman KJ, Loughlin JE, Dreyer NA. Utility of telephone company records for epidemiologic studies of cellular telephones. Epidemiology. 1996 May 7;7(3):299-302.